NCT03992937View on ClinicalTrials.gov

Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia

NACompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Endometrial Hyperplasia Without Atypia
Interventions
DRUG

Vaginal Micronized Progesterone

Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.

DEVICE

Levonorgestrel-Intrauterine System

Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.

Trial Locations (1)

41380

Kocaeli University, Kocaeli

All Listed Sponsors
lead

Kocaeli University

OTHER

NCT03992937 - Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia | Biotech Hunter | Biotech Hunter